AstraZeneca to Invest $50 Billion in U.S. Manufacturing and R&D, Leveraging AI and Automation

AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh

The office building of international biopharmaceutical company AstraZeneca. AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs. The Anglo-Swedish biotech company, which is headquartered in Cambridge, England, said the "cornerstone" of the commitment would be a new multi-billion dollar facility to produce its weight management and metabolic portfolio, including its oral GLP-1 obesity pill. The facility, planned for the Commonwealth of Virginia, is set to be AstraZeneca's largest single manufacturing investment in the world and will "leverage AI, automation and data analytics to optimize production," the company said. The latest funding will also expand research and development and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, and create "tens of thousands of jobs," AstraZeneca added. CEO Pascal Soriot said the commitment underpins the firm's "belief in America's innovation in biopharmaceuticals" and would support its ambition to reach $80 billion in annual revenue by 2030, half of which is expected to come from the U.S. AstraZeneca, which made international headlines by developing one of the key Covid-19 vaccines, has long been prioritizing the U.S. market. The United States accounted for over 40% of the company's annual revenues in 2024. In November, shortly after the U.S. presidential election, AstraZeneca announced a $3.5 billion U.S. investment. Earlier this month, The Times reported that the firm may move its listing from London to the U.S., in what analysts said would be a major blow to the U.K.'s public markets. AstraZeneca is the most valuable business listed on London's FTSE 100. The company declined to comment on the Times report.

AstraZeneca invests $50B in U.S. as pharma giants seeks to avoid Trump tariffs

AstraZeneca today announced it will invest $50 billion in the U.S. by 2030 to fund manufacturing and research and development (R&D). The investment is expected to create tens of thousands of new, highly-skilled direct and indirect jobs across the country, the company said in a statement. The cornerstone of the investment is a new multi-billion dollar manufacturing facility in Virginia that will produce substances used in the company's weight management and metabolic portfolio. This includes GLP-1, the substance used in Novo Nordisk's Ozempic, which AstraZeneca has been seeking to replicate. The facility would be AstraZeneca's largest single manufacturing investment in the world and will leverage artificial intelligence and robotics to optimize production. "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally," Pascal Soriot, AstraZeneca CEO, said in a statement. Shares in AstraZeneca rose 2% at market open. The investment will also go towards expanding manufacturing in Maryland, Texas, Indiana, and California, plus growing R&D centres, research into novel medicines, and new sites to supply clinical trials Tuesday's investment builds on the $3.5 billion AstraZeneca announced in November 2024. It hopes collectively these investments will help it to deliver its goal of reaching $80 billion in revenue by the end of the decade, with 50% generated in the U.S., according to the company statement. AstraZeneca is the latest pharmaceutical company to pledge billions in domestic manufacturing in recent months, joining the likes of Biogen, Eli Lilly, Johnson & Johnson, Novartis, and Roche. So far this year, pharma companies have pledged to invest $231.3 billion in the U.S. in the coming years. The flurry of fresh capital could be seen as an attempt to appease President Donald Trump. During a Cabinet meeting earlier this month, Trump said a pharma tariff of up to 200% is coming "very soon." This could prove catastrophic for drug prices. Non-branded drugs account for 90% of prescriptions filled in the U.S., and around 70-80% of these generics are imported from China and India. "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness," said U.S. Secretary of Commerce Howard Lutnick. "We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores."

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US - AstraZeneca (NASDAQ:AZN)

AstraZeneca plc AZN announced on Tuesday that it will invest $50 billion in the United States by 2030. The investment will create new, highly skilled direct and indirect jobs nationwide, the company said. The cornerstone of this landmark investment is a new multi-billion-dollar U.S. manufacturing facility that will produce drug substances for the company's weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small-molecule products. The new centre will produce small molecules, peptides, and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned for the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. It will leverage AI, automation, and data analytics to optimize production. Trending Investment OpportunitiesAdvertisementArrivedBuy shares of homes and vacation rentals for as little as $100. Get StartedWiserAdvisorGet matched with a trusted, local financial advisor for free.Get StartedPoint.comTap into your home's equity to consolidate debt or fund a renovation.Get StartedRobinhoodMove your 401k to Robinhood and get a 3% match on deposits.Get StartedWhat Does The Investment Include? The $50 billion investment across R&D and manufacturing footprint in the U.S. over the next five years also includes: Expansion of R&D facility in Gaithersburg, Maryland R&D centre in Kendall Square, Cambridge, Massachusetts Manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California Manufacturing expansion in Mount Vernon, Indiana Specialty manufacturing expansion in Coppell, Texas New sites to supply clinical trials. The company said collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which 50% would be generated in the U.S. Howard Lutnick, U.S. Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores." Amid tariff uncertainty, many drug companies are investing to boost production within the U.S. Most recently, Biogen Inc. BIIB said that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park (RTP). Eli Lilly And Co LLY doubled domestic medicine production. Thermo Fisher Scientific Inc. TMO announced it would invest an additional $2 billion in the U.S. over the next four years. Medtech firm Becton, Dickinson, and Company BDX also announced its intention to invest $2.5 billion in U.S. manufacturing capacity over the next five years. Regeneron Pharmaceuticals, Inc. REGN seeks to nearly double its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies. Novartis AG NVS unveiled a $23 billion investment plan to expand in the U.S. over the next five years. Johnson & Johnson JNJ plans to invest more than $55 billion in the U.S. over the next four years. Roche Holdings AG RHHBY announced that it will invest $50 billion in the U.S. over the next five years. Bristol-Myers Squibb & Co.'s BMY Christopher Boerner, chair and chief executive officer, shared plans to invest $40 billion in U.S. R&D, technology, and manufacturing over the next five years. Sanofi SA SNY announced it will invest at least $20 billion in the U.S. through 2030. The bulk of the spending will go to R&D and U.S. manufacturing. Price Action: AZN stock is up 2.34% at $70.33 at the last check on Tuesday Read Next: Pony AI Stock Surges As Autonomous System Hits Key Milestone Photo by JHVEPhoto via Shutterstock AZNAstraZeneca PLC$70.292.28%Stock Score Locked: Edge Members Only Benzinga Rankings give you vital metrics on any stock - anytime. Unlock RankingsEdge RankingsMomentum33.79Growth79.59Quality59.98Value23.28Price TrendShortMediumLongOverviewBDXBecton Dickinson & Co$179.852.58%BIIBBiogen Inc$126.653.24%BMYBristol-Myers Squibb Co$47.862.50%JNJJohnson & Johnson$166.831.50%LLYEli Lilly and Co$773.531.49%NVSNovartis AG$116.381.96%REGNRegeneron Pharmaceuticals Inc$556.081.93%RHHBYRoche Holding AG$39.990.50%SNYSanofi SA$48.651.49%TMOThermo Fisher Scientific Inc$423.274.53%Market News and Data brought to you by Benzinga APIs

AstraZeneca to invest USD50 billion in US facilities by 2030

(Alliance News) - AstraZeneca PLC on Monday announced plans to invest billions of dollars into its US medicines manufacturing and research and development capabilities. The Cambridge, England-based pharmaceutical company intends to invest USD50 billion in the US by 2030, with the focus of the investment being a proposed drug substance manufacturing centre in Virginia. "[The facility] will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products," AstraZeneca said. "The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the USD3.5 billion announced in November 2024." AstraZeneca said the Virginia facility will leverage artificial intelligence, automation, and data analytics to optimise production processes, with the proposal standing out as the company's largest single investment in a facility to date. Other investments will support research and development capabilities in Maryland and Massachusetts, along with manufacturing capabilities in California, Indiana, Maryland, and Texas. "Collectively, these investments will help deliver AstraZeneca's ambition of reaching USD80 billion in total revenue by 2030, of which we expect 50% would be generated in the US," the company said. In full year 2024, AstraZeneca generated USD54.07 billion in revenue, meaning the 2030 goal reflects a 48% increase. AstraZeneca shares closed down 0.3% at 10,262.00 pence each in London on Tuesday. By Elijah Dale, Alliance News senior reporter Asia-Pacific Comments and questions to [email protected] Copyright 2025 Alliance News Ltd. All Rights Reserved.

AstraZeneca: set to invest $50bn in US

AstraZeneca announced on Tuesday that it plans to invest some $50bn in United States by 2030, against a backdrop of tougher US protectionist trade policies that are also affecting the pharmaceutical sector. The Anglo-Swedish laboratory, which had already announced in November 2024 a $3.5bn investment in the US market, explained that the cornerstone of the project will be the construction of a state-of-the-art small molecule manufacturing facility in Virginia, which will become its largest production site worldwide. The new facility, which will be equipped with the latest AI, industrial automation, and data analysis technologies, will focus primarily on developing drugs for obesity, hypertension, and cholesterol. In total, AstraZeneca plans to create tens of thousands of jobs in the US, including through the expansion and modernization of other R&D and manufacturing sites in Maryland, Massachusetts, California, Indiana, and Texas. In its press release, the biopharmaceutical giant emphasized that these plans are part of its strategy to achieve total revenue of $80bn by 2030, with 50% coming from the US (compared with 42% currently). Unsurprisingly, these announcements were welcomed by Washington, which is seeking to strengthen the national industrial fabric by putting in place strong import barriers, including in the healthcare sector. "For decades, Americans have been dependent on foreign supplies for essential pharmaceutical products," commented Howard Lutnick, US Secretary of Commerce. "President Trump and our new tariff policies aim to end this structural weakness," he explained. In his view, this "historic" investment will ensure that drugs sold in the United States will now also be manufactured there. On the London Stock Exchange, AstraZeneca shares fell 0.2% in the wake of this news, in a fairly flat British stockmarket in early trading.

AstraZeneca Plans to Invest $50 Billion in America for Medicines Manufacturing and R&D

AstraZeneca announced $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production. The $50 billion investment across R&D and manufacturing footprint in the US over the next five years also includes: Expansion of R&D facility in Gaithersburg, Maryland; R&D centre in Kendall Square, Cambridge, Massachusetts; Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; Continuous manufacturing expansion in Mount Vernon, Indiana; Specialty manufacturing expansion in Coppell, Texas; New sites to supply clinical trials; growing research and development investment in novel medicines; Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which expect 50% would be generated in the US.